Xortx Therapeutics Stock Return On Asset

XRTX Stock  USD 1.27  0.06  4.96%   
XORTX Therapeutics fundamentals help investors to digest information that contributes to XORTX Therapeutics' financial success or failures. It also enables traders to predict the movement of XORTX Stock. The fundamental analysis module provides a way to measure XORTX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XORTX Therapeutics stock.
Return On Assets is likely to drop to -0.42 in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

XORTX Therapeutics Company Return On Asset Analysis

XORTX Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current XORTX Therapeutics Return On Asset

    
  -0.33  
Most of XORTX Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XORTX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

XORTX Return On Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for XORTX Therapeutics is extremely important. It helps to project a fair market value of XORTX Stock properly, considering its historical fundamentals such as Return On Asset. Since XORTX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XORTX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XORTX Therapeutics' interrelated accounts and indicators.
0.98-0.99-0.580.530.760.891.0-0.43-0.740.910.56-0.150.97-0.621.00.840.730.92-0.15
0.98-0.98-0.550.390.710.80.98-0.45-0.750.920.56-0.170.99-0.580.990.830.730.93-0.17
-0.99-0.980.51-0.51-0.73-0.88-0.990.380.7-0.89-0.480.12-0.970.54-0.99-0.79-0.67-0.890.12
-0.58-0.550.51-0.49-0.82-0.49-0.550.770.86-0.78-0.90.71-0.530.85-0.59-0.89-0.88-0.770.71
0.530.39-0.51-0.490.670.830.52-0.23-0.30.330.440.110.34-0.560.490.530.350.370.11
0.760.71-0.73-0.820.670.740.74-0.65-0.780.780.77-0.350.65-0.720.750.90.750.81-0.35
0.890.8-0.88-0.490.830.740.89-0.27-0.540.680.460.080.78-0.570.860.710.560.710.08
1.00.98-0.99-0.550.520.740.89-0.42-0.710.890.54-0.130.97-0.611.00.820.710.9-0.13
-0.43-0.450.380.77-0.23-0.65-0.27-0.420.58-0.61-0.840.56-0.430.83-0.46-0.73-0.67-0.580.56
-0.74-0.750.70.86-0.3-0.78-0.54-0.710.58-0.91-0.710.65-0.730.62-0.75-0.89-0.95-0.920.65
0.910.92-0.89-0.780.330.780.680.89-0.61-0.910.7-0.530.92-0.680.930.910.870.98-0.53
0.560.56-0.48-0.90.440.770.460.54-0.84-0.710.7-0.480.54-0.940.570.90.780.72-0.48
-0.15-0.170.120.710.11-0.350.08-0.130.560.65-0.53-0.48-0.210.41-0.2-0.44-0.61-0.441.0
0.970.99-0.97-0.530.340.650.780.97-0.43-0.730.920.54-0.21-0.580.980.810.710.92-0.21
-0.62-0.580.540.85-0.56-0.72-0.57-0.610.830.62-0.68-0.940.41-0.58-0.63-0.86-0.76-0.670.41
1.00.99-0.99-0.590.490.750.861.0-0.46-0.750.930.57-0.20.98-0.630.850.750.93-0.2
0.840.83-0.79-0.890.530.90.710.82-0.73-0.890.910.9-0.440.81-0.860.850.90.94-0.44
0.730.73-0.67-0.880.350.750.560.71-0.67-0.950.870.78-0.610.71-0.760.750.90.88-0.61
0.920.93-0.89-0.770.370.810.710.9-0.58-0.920.980.72-0.440.92-0.670.930.940.88-0.44
-0.15-0.170.120.710.11-0.350.08-0.130.560.65-0.53-0.481.0-0.210.41-0.2-0.44-0.61-0.44
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

XORTX Total Assets

Total Assets

4.97 Million

At this time, XORTX Therapeutics' Total Assets are fairly stable compared to the past year.
Based on the latest financial disclosure, XORTX Therapeutics has a Return On Asset of -0.3314. This is 96.21% lower than that of the Biotechnology sector and 98.6% lower than that of the Health Care industry. The return on asset for all United States stocks is 136.71% higher than that of the company.

XORTX Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XORTX Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XORTX Therapeutics could also be used in its relative valuation, which is a method of valuing XORTX Therapeutics by comparing valuation metrics of similar companies.
XORTX Therapeutics is currently under evaluation in return on asset category among its peers.

XORTX Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of XORTX Therapeutics from analyzing XORTX Therapeutics' financial statements. These drivers represent accounts that assess XORTX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XORTX Therapeutics' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap8.0M10.1M11.3M134.3M5.7M5.5M
Enterprise Value7.8M10.1M11.2M123.9M2.3M2.2M

XORTX Fundamentals

About XORTX Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze XORTX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XORTX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XORTX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.